Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Gyre Therapeutics Logo
Gyre Therapeutics Growth Score
65
CB Rank
48096
Heat Score
62
Gyre Therapeutics is a biopharmaceutical company that offers protease therapeutics to address disorders of the coagulation system.
Founded
obfuscation
PublicPost-IPO Equity South San Francisco, California, United States51-100 www.gyretx.com
Biopharma
Biotechnology
Life Science
Pharmaceutical
Overview

Gyre Therapeutics
Total Funding
obfuscation
Growth Score
65
Heat Score
62

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score65
-16 pts
in past quarter
Heat Score 62
-12 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Gyre Therapeutics

CB Rank
48096
Gyre Therapeutics is a biopharmaceutical company that offers protease therapeutics to address disorders of the coagulation system.
Founded
obfuscation
PublicPost-IPO Equity South San Francisco, California, United States51-100 www.gyretx.com
Biopharma
Biotechnology
Life Science
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

Details

Legal Name Catalyst Biosciences, Inc.
Also Known As Targacept, Inc., Catalyst Biosciences
Operating Status Active
Stock Symbol  NASDAQ:GYRE
Company Type For Profit
Founders  Charles S. Craik, Christopher Thanos, Jack Nguyen, Sandra Waugh Ruggles
About the Company
Gyre Therapeutics is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.
Phone Number +1 844-556-7246
Contact Email info@gyretx.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Gyre Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

F230
A therapeutic candidate for treating pulmonary arterial hypertension by targeting organ fibrosis and inflammatory pathways.

Research & Development

Gyre Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 15
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 15
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Gyre Therapeutics Logo
Post-IPO Equity - Gyre Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 5 Board Members and Advisors 10 Contacts 42

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 28, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,235
30.83%
 in past month

IT Spend

$2.2MThis year, Gyre Therapeutics is projected to spend $2.2M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Kickoff Logo
Kickoff
77
Payroll Logo
Payroll
72
Payroll Services Logo
Payroll Services
72

Active Website Tech Count

10Gyre Therapeutics is actively using 10 technologies for its website, according to BuiltWith. These include HSTS, CommonCrawl Top 10m, and  jQuery CDN.

Total IP

18The intellectual property of Gyre Therapeutics includes 18 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations

Sub-Organizations

Number of Sub-Orgs 1
Which industries do these Sub-Organization operate in?
Cullgen Logo
CullgenSubsidiary
Frequently Asked Questions

Where is Gyre Therapeutics's headquarters? Gyre Therapeutics is located in South San Francisco, California, United States.Who invested in Gyre Therapeutics? Gyre Therapeutics has 24 investors including Essex Woodlands Healthcare Partners and  HealthCare Ventures.When was the last funding round for Gyre Therapeutics? Gyre Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Gyre Therapeutics's competitors? Alternatives and possible competitors to Gyre Therapeutics may include Roivant Sciences, Insmed, and  Aerovate Therapeutics.How much funding has Gyre Therapeutics raised to date? Gyre Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3120884 1)
|